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Abstract  34 
Objective:  To assess drug susceptibility and characterize C. difficile ribotypes in 35 
isolates from two tertiary-care hospitals in Mexico. 36 
Methods: Isolates were evaluated for genotyping, antimicrobial susceptibility 37 
testing and detection of mutations associated with drug resistance. PCR ribotyping was 38 
performed using a combination of gel-based and capillary electrophoresis-based 39 
approaches.  40 
Results:  MIC50 and MIC90 were ≥128 mg/L for ciprofloxacin, erythromycin, 41 
clindamycin, and rifampicin. There was no reduced susceptibility to metronidazole or 42 
tetracycline; however, reduced susceptibility to vancomycin (≥4 mg/L) and fidaxomicin 43 
(≥2 mg/L) was detected in 50 (40.3%) and 4 (3.2%) isolates respectively.  Furthermore, 44 
the rpoB Arg505Lys mutation was more frequently detected in isolates with high MIC to 45 
rifampicin (≥32 mg/L) (OR = 52.5; 95% CI = 5.17- 532.6; p < 0.000). 46 
Of the 124 C. difficile isolates recovered; 84 (66.7%) were of ribotype 027, 18 47 
(14.5%) of ribotype 001, and the remainder were other ribotypes (353, 255, 220, 208, 176, 48 
106, 076, 020, 019, 017, 014, 012, 003, and 002).  49 
Conclusion:  Ribotypes 027 and 001 were the most frequent C. difficile isolates 50 
recovered in this study, and demonstrated higher MICs. Furthermore, we found four 51 
isolates with reduced susceptibility to fidaxomicin, raising a concern since this drug is 52 
currently unavailable in Mexican Hospitals. 53 
 54 
Keywords: Drug resistance; Ribotypes; Fidaxomicin; Ribotype 001; Clostridium difficile. 55 
 56 




C. difficile infection (CDI) symptoms may range from mild diarrhea to life-58 
threatening complications. Apart from NAP1/BI/027, other C. difficile ribotypes have been 59 
associated with severe disease, e.g. ribotype 078 affects younger patients and is a frequent 60 
causative agent of community-associated disease 1; ribotype 001 is the dominant strain in 61 
eastern Europe and has higher antimicrobial resistance than other ribotypes 2.  62 
First-line treatment for mild to moderate CDI is based on oral administration of 63 
metronidazole or vancomycin, with a therapeutic efficacy >70% 3. In some patients, 64 
however, diarrheal symptoms may reappear within days or weeks after having stopped the 65 
treatment. Fidaxomicin is a relatively new narrow-spectrum macrocyclic antibiotic drug 66 
that is non-inferior to vancomycin in the management of CDI and associated with lower 67 
recurrence rates than vancomycin4. However, fidaxomicin is currently unavailable in 68 
Mexico, thus vancomycin and metronidazole are still the standard treatments for CDI as 69 
recommended in the Clinical Practice Guidelines for C. difficile Infection in Adults of the 70 
Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases 71 
Society of America (IDSA). Other therapeutic options that have been proposed in recent 72 
years are rifamycins (good in vitro activity against C. difficile) including rifaximin (for 73 
relapsing CDI) 5, and linezolid (protective rather than curative activity) 6.  74 
Resistance to erythromycin may be due to any of more than 20 classes of 75 
erythromycin ribosomal methylase (erm) genes, including ermB 7, which is also related to 76 
clindamycin resistance. In C. difficile, resistance to fluoroquinolones is usually due to 77 
altered DNA gyrase because of nucleotide substitutions in gyrA or gyrB genes 5. Resistance 78 
to rifamycins or fidaxomicin is mediated by mutations that lead to reduced binding to the β 79 
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subunit of RNA polymerase (RpoB) 7,8. Finally, resistance to linezolid has been related to 80 
the presence of the phenicol and lincosamide resistance gene (cfr), as described for 81 
staphylococci 9. 82 
Although C. difficile is an important nosocomial pathogen, little is known about the 83 
epidemiology of this microorganism in Mexico. The aims of the present study were to 84 
determine the drug susceptibility of Mexican C. difficile isolates, particularly to the recently 85 
licensed CDI treatment, fidaxomicin, and to study circulating ribotypes in two tertiary-care 86 




Settings and study population  91 
  We designed an observational study of circulating C. difficile ribotypes, drug 92 
susceptibility, and drug resistance genes from two hospitals in Mexico: The Hospital Civil 93 
of Guadalajara “Fray Antonio Alcalde”, is a 1000-bed tertiary-care teaching hospital, in 94 
Guadalajara; and the Hospital Universitario “Dr. José Eleuterio González”, is a 450-bed 95 
tertiary-care teaching hospital in Monterrey.  96 
All patients with confirmed CDI from February 2011 through January 2016 were 97 
included in the study. Recurrences were defined as patients with a reappearance of 98 
symptoms after resolution of the previous diarrheal episode within 8 weeks or less. As 99 
patient information was anonymized and only microbiological data were analyzed, 100 
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informed consent was not required. The study was reviewed and approved by the Local 101 
Ethics Committee (Approval: 047/16). 102 
 103 
Diagnosis of Clostridium difficile infection 104 
Clinical diagnosis of CDI was suspected when patients were hospitalized for more 105 
than 48 h and had >3 loose stools in the previous 24 h. In the Hospital Civil of Guadalajara, 106 
CDI was confirmed by real-time PCR using the Xpert® C. difficile/Epi assay (Cepheid, 107 
Sunny Vale, CA, USA) and in the Hospital Universitario, the diagnosis was confirmed by 108 
the use of the Meridian ImmunoCard ® Toxins A&B (Meridian Bioscience, Inc., Memphis, 109 
TN, USA). Some patients were additionally diagnosed by the Xpert® C. difficile/Epi assay 110 
in Hospital Universitario only at physicians’ request. 111 
 112 
Culture 113 
Fecal samples from all confirmed CDI cases were treated with absolute ethanol and 114 
cultured on C. difficile agar (Neogen Corporation, MI, USA) with cefoxitin (16 mg/L) in 115 
anaerobic conditions for up to 72 h. Plates were cultured in either an anaerobic jar or 116 
anaerobic chamber. Identification was performed by PCR as described 10. Only one isolate 117 
per patient was included in the study.  118 
 119 
Antimicrobial susceptibility testing  120 
We tested antimicrobial agents used for CDI treatment such as vancomycin, 121 
metronidazole (range from 0.03 mg/L to 128 mg/L), fidaxomicin (range from 0.002 to 8 122 
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mg/L), and rifampicin (range from 0.0001 mg/L to 128 mg/L); and also antimicrobials with 123 
potential therapeutic use such as linezolid (range from 0.03 mg/L to 128 mg/L). 124 
Furthermore, we tested antimicrobials that may be associated with induction of CDI, 125 
including ciprofloxacin, moxifloxacin, erythromycin, clindamycin (range from 0.03 mg/L 126 
to 128 mg/L), and tetracycline (range from 0.008 mg/L to 128 mg/L). 127 
Susceptibility testing was performed by the agar dilution method using Wilkins-128 
Chalgren agar (Oxoid Limited, Basingstoke, Hampshire, England) and Schaedler’s 129 
anaerobe broth (Oxoid Limited) 11. Briefly, overnight cultures in 5 ml of pre-reduced 130 
Schaedler’s broth were spotted onto plates of Wilkins-Chalgren agar with different 131 
concentrations of antibiotics, using a multipoint inoculator (104 colony-forming units/spot). 132 
An agar plate without an antimicrobial agent was included as a growth control in both 133 
aerobic and anaerobic atmosphere and the plates were read after 48 h of incubation at 37°C 134 
in an anaerobic environment. C. difficile ATCC 700057 was used as quality control.  135 
 A stock solution of fidaxomicin (800 mg/L), was prepared in DMSO, then 1 ml of 136 
stock was diluted in 5 ml of DMSO and 4 ml of 10% DMSO (final concentrations 80 137 
mg/L); further dilutions were made in 10% DMSO. Stock solutions of remaining antibiotics 138 
(2560 mg/L) and dilutions were dissolved accordingly to recommendations of the Clinical 139 
and Laboratory Standards Institute (CLSI) document M100-S27. 140 
 141 
Mutations associated with drug resistance 142 
To detect mutations associated with resistance to rifampicin or fidaxomicin, two 143 
regions of the rpoB gene were amplified; for rifampicin, we used previously reported 144 
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primers 9, and for fidaxomicin, we designed the primers CdrpoB-FD-F (5'-145 
TCATGGAAAATGGAACACCA-3') and CdrpoB-FD-R (5'-146 
CCAAACCTCCATCTCTCCAA-3'). We designed the primers CdrpoC-VAN-F (5'-147 
GAATGGGTGCTGAAGCTGTA-3) and CdrpoC-VAN-R (5'-148 
GACGGAAACGACCTTGCTTA -3 ') to amplify a region in the rpoC gene that has been 149 
linked to vancomycin resistance12. Furthermore, the presence of the cfr gene was 150 
investigated by PCR in selected strains as previously described 13. 151 
Sequencing of PCR-purified products was performed by Macrogen Inc. (Seoul, 152 
Korea). The sequences were analyzed using the NCBI Basic Local Alignment Search Tool 153 
(BLAST). 154 
 155 
Typing of isolates 156 
All isolates were typed for tcdA, tcdB, cdtA, cdtB, and for deletions in tcdC by PCR 157 
as previously described 14,15. For ribotyping, amplification of the 16S-23S rRNA intergenic 158 
spacer region was conducted by PCR as described 16. The ATCC strain BAA-1805 159 
(ribotype 027) was used as a control. Selected isolates were ribotyped by capillary 160 
electrophoresis at the C. difficile Ribotyping Network Reference Laboratory (CDRN) at 161 
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Culture   166 
Samples were cultured in anaerobic jar (n=196, 57.1%) or in anaerobic chamber 167 
(n=147, 42.9%). In total, we cultured 343 samples, of which 124 (36.1%) yielded a positive 168 
C. difficile culture (one isolate per patient). Most of the cases were from the Hospital Civil 169 
of Guadalajara (n = 76, 61.3%); the Hospital Universitario accounted for 48 of the cases 170 
(38.7%). 171 
 172 
Antimicrobial susceptibility profiles  173 
Four isolates (3.2%) had reduced susceptibility to fidaxomicin (MIC = 2 mg/L), 174 
whereas no isolate was resistant to either tetracycline or metronidazole. MIC50 and MIC90 175 
were ≥128 mg/L to ciprofloxacin, erythromycin, clindamycin, and rifampicin (Table 1). 176 
MIC distributions of CDI treatment drugs (vancomycin, metronidazole and fidaxomicin) 177 
are shown in Figure 1. 178 
 179 
Molecular analysis of drug resistance 180 
When analyzing a region of rpoB in fidaxomicin-susceptible isolates (n= 18) and 181 
isolates with reduced susceptibility (n=3), we found 7 mutations; one of these caused an 182 
amino acid change that was not associated to reduced susceptibility strains (Table 2). 183 
Furthermore, the rpoB gene was amplified and partially sequenced in 14 rifampicin-184 
susceptible and 22 rifampicin-resistant isolates. We detected 3 mutations that generated 185 
amino acid changes in both susceptible and resistant isolates; the Arg505Lys mutation was 186 
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more frequently detected in resistant isolates (21/22, 95.4%) than in susceptible isolates 187 
(4/14, 28.5%) (OR = 52.5; 95% CI = 5.17- 532.6; p<0.000) (Table 2). 188 
We also analyzed the rpoC gene in 14 vancomycin-susceptible isolates and 12 189 
isolates with reduced susceptibility to vancomycin and detected 22 mutations; two of them 190 
were associated with an amino acid change (Table 2). The presence of drug resistance 191 
genes was analysed in selected isolates (i.e. isolates with the highest and lowest MIC 192 
values). The cfr gene was not amplified in any of the  linezolid-susceptible (n=17) or 193 
linezolid-resistant (n=9) C. difficile isolates evaluated.  194 
 195 
Ribotypes  196 
Toxin A and toxin B genes were detected in all isolates. The binary toxin gene was 197 
detected in 89 isolates (71.8%), of which 87 (97.8%) contained the tcdC 18-bp deletion 198 
(Table 3).  199 
Eighty-four isolates (67.7%) demonstrated the same ribotype banding patterns to the 200 
control strain BAA-1805 (ribotype 027) (Table 2) and we randomly selected twelve strains 201 
that were all confirmed to be ribotype 027 by the CDRN (Leeds, UK). Similarly, of 18 202 
isolates (14.5%) that demonstrated similar banding pattern to ribotype 001 (90% of 203 
similarity), four randomly selected isolates were confirmed to be ribotype 001 by the 204 
CDRN (Leeds, UK). The ribotypes and presence of toxin genes of the other isolates are 205 
summarized in table 3. 206 
 207 




In our study, ribotype 027 was the predominant strain, accounting for 67.7% of the 209 
cases; this ribotype is considered epidemic and has been reported worldwide17. In previous 210 
publications we have found 027 strain as the predominant ribotype in our settings 18,19, the 211 
latter is in contrast to diverse studies were there is a high diversity of ribotypes and 027 212 
stains account for less than 30% 20-22. The second most frequent ribotype was 001, 213 
accounting for 14.5% of the cases; this ribotype is the main ribotype circulating in Korea 23, 214 
Czech Republic 2, Croatia 24, and Slovakia 25, however, this is the first report on ribotype 215 
001 circulation in Mexico. This strain has been associated with high drug resistance, 216 
including resistance to ciprofloxacin, erythromycin, and clindamycin24. 217 
Fidaxomicin is an FDA-approved antibiotic for the treatment of CDI8. A previous 218 
study that included 1,323 isolates showed a MIC90 of 0.5 mg/L against C. difficile26; 219 
similarly, Snydman et al reported 925 isolates that were inhibited at a fidaxomicin 220 
concentration ≤1 mg/L, and the MIC90 was 0.5 mg/L 20. In the present study, we observed a 221 
MIC90 of 0.06 mg/L; however, we detected 4 ribotype 027 isolates with a fidaxomicin MIC 222 
of 2 mg/L; these isolates were recovered from patients with recurrent CDI. This finding is 223 
of interest since fidaxomicin is unavailable in Mexican hospitals and none of the patients 224 
included in the study were exposed to this drug. However, we performed susceptibility 225 
testing only once; nevertheless, the MIC of control strain were reproducible and the four 226 
strains with MIC = 2 mg/L were detected in a batch of 36 isolates being tested at the same 227 
time. MICs of the remaining 32 isolates were ≤0.125 mg/L. 228 
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Reduced susceptibility to fidaxomicin may be due to point mutations in the rpoB 229 
gene (RNA polymerase subunit β) 12. We detected one point mutation (Glu1036Gln) in 230 
RpoB, but it was not associated with drug resistance (P = 0.489). Leeds et al. identified two 231 
mutations in rpoB that were associated with reduced susceptibility to fidaxomicin; one of 232 
them coded a Gln1073Arg substitution and the second was a frameshift after amino acid 233 
117 of a homolog of the MarR family of transcriptional regulators 12; however, we did not 234 
detect these mutations in our strains. Other mutations associated with fidaxomicin reduced 235 
susceptibility have been reported, but all of them have been obtained through the serial 236 
passage of strains into media containing fidaxomicin 27. Goldstein et al. isolated a strain 237 
with a MIC of 16 mg/L to fidaxomicin from a patient with an episode of recurrence during 238 
a clinical trial 28; this isolate harbored a Val1143Gly substitution in rpoB. However, the 239 
authors did not consider that resistance had developed during the clinical trial and did not 240 
explain the clinical relevance of this finding. To our knowledge, there is no report of 241 
clinical resistance to fidaxomicin. It is widely known that fidaxomicin reaches high levels 242 
in the gut (1,000 µg/g of faeces) 28; thus, the actual implication of the high MIC in the 243 
strains is unknown, considering the lack of reports on clinical resistance and particularly in 244 
Mexico, where this drug is not available. 245 
In our study, we detected reduced susceptibility to vancomycin of 40.3% with 246 
48.8% of reduced susceptibility in 027 strains and 33.3% in 001 strains; proportions as high 247 
as 87.7% have been reported in ribotype 027 strains 29. Similarly, to fidaxomicin, it is 248 
unlikely that reduced susceptibility impacts on clinical response, due to the high levels of 249 
vancomycin reached in the gut (>2000 mg/L); however, among patients from whom we 250 
recovered isolates with reduced susceptibility (50 patients), nine died because of CDI and 251 
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five of these patients received vancomycin. Nevertheless, other factors may have acted in 252 
these patients’ response to treatment. 253 
Although this bacterial species has a vanG homolog inducible by vancomycin, it 254 
does not promote vancomycin resistance 30. Leeds et al. identified an Asp244Tyr 255 
substitution in rpoC that was associated with reduced susceptibility to vancomycin 12. 256 
Despite our efforts to detect this mutation, it was not found. Leeds et al. reported additional 257 
mutations: a Pro108Leu substitution in a transferase encoded by murG/CD2725, a stop 258 
codon after amino acid 326 in an exonuclease encoded by CD3659, and a single amino acid 259 
deletion in an L-serine dehydrogenase (sdaB). Therefore, it seems that diverse mechanisms 260 
are responsible for reduced susceptibility to vancomycin, particularly those involved in cell 261 
wall biosynthesis.  262 
On the other hand, we observed no resistance to metronidazole; similar findings 263 
have been reported in other studies 21,31. Clinical failures with metronidazole treatments 264 
have been attributed to the development of heteroresistance and deficiencies in the 265 
pharmacokinetics of the drug resulting in low luminal concentrations following oral 266 
administration. Resistance to metronidazole is known to be unstable, with the loss of levels 267 
of resistance due to laboratory manipulation 5.  268 
High MICs to linezolid has occasionally been described in C. difficile 9,32. 269 
Interestingly, the isolates of ribotype 001 showed higher MICs (8-32 mg/L) than 027 270 
isolates (8 mg/L).Although linezolid is not used for the treatment of CDI, linezolid is 271 
widely used in the Hospital Civil of Guadalajara for the treatment of nosocomial 272 
pneumonia, surgical wound infections, and bloodstream infections not associated with a 273 
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catheter. Marín et al. found nine isolates resistant to linezolid and were cfr-positive C. 274 
difficile isolates that belonged to the same clonal cluster, suggesting possible horizontal 275 
transmission of these strains among patients in their hospital setting 9. However, we did not 276 
detect the cfr gene in any of the selected C. difficile isolates we studied.  277 
We also found a high proportion of isolates with elevated MICs to rifampicin in 027 278 
strains (95.2%) and 001 strains (83.3%). In contrast, Tenover et al found lower proportions 279 
(27.5%) of isolates with high MIC to rifampicin 21. For this antimicrobial agent, a bimodal 280 
distribution of MICs has been reported; Norén et al. found 80% of strains to with low MIC 281 
(>0.016 mg/L) or high MIC (>256 mg/L) 33. In our isolates, we detected three previously 282 
reported amino acid substitutions in RpoB associated with rifampicin resistance: 283 
Arg505Lys, His502Asn, and Ile548Met. Curry et al 13 reported all three changes, including 284 
Arg505Lys, which was present in isolates with MICs >32 mg/L. We also confirmed the 285 
importance of this mutation in rifampicin-resistant isolates (OR = 52.5, CI 5.17- 532.6, p = 286 
0.000). Similarly, the authors reported an Ile548Met change in isolates with MICs >32 287 
mg/L, however, in the C. difficile strains evaluated in the present study, this change was not 288 
associated with rifampicin resistance (p = 0.074). 289 
Our study has some limitations. First, we were unable to recover all isolates from all 290 
samples, in fact, the recovery rate was low. The low recuperation can be attributed to the 291 
medium used, which does not incorporate sodium taurocholate as spore germinant; and the 292 
use of ethanol to eliminate any vegetative organisms that survived freezing. Consequently, 293 
the isolates are not homogeneously distributed throughout the study period, making it 294 
difficult to study distribution over time, and perhaps generating bias on ribotype 295 
prevalence; second, clinical diagnosis was not confirmed in a uniform way. Apart from 296 
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differences in diagnosis, this may have contributed to the low recovery of isolates; and 297 
finally, data of ribotyping in 027 and 001 strains were mainly extrapolated from primary 298 
results of conventional electrophoresis.  299 
In conclusion, this is the first report on drug susceptibility of C. difficile ribotypes 300 
circulating in Mexico. Ribotypes 027 and 001 were the most frequent and highly drug 301 
resistant; furthermore, we found four isolates with reduced susceptibility to fidaxomicin, 302 
raising a concern since this drug is unavailable in Mexican Hospitals. The clinical relevance 303 
of these findings needs to be addressed to fully understand the epidemiology of CDI in 304 
Mexican hospitals. 305 
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